SUPERA® Stent Approved for Private Reimbursement in Australia

- IDEV Technologies Continues Expansion in Asia Pacific Region

WEBSTER, Texas, Sept. 28, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV), an emerging global innovator in peripheral devices, today announced that Private Healthcare Australia has granted the Company a reimbursement code for the SUPERA® stent.  The August 2012 Prostheses List was effective August 30, 2012.  This is an important milestone as the Company continues to build a solid foundation in the Asia Pacific region. 

"Gaining the private reimbursement code opens a significant portion of the Australian market to this exciting technology," commented Trent Reutiman, IDEV's Vice President of Global Commercial Operations.  "Working closely with our distributor in Australia and New Zealand, Device Technologies, we will be able to move quickly to provide the SUPERA stent to physicians who have been awaiting reimbursement."

"This is critically important as we implement our long term strategy in the Asia Pacific region, one of the fastest growing global markets. We are pleased that Private Healthcare Australia has recognized the benefits of our technology by granting the reimbursement codes," said Christopher Owens, President and CEO of IDEV. 

In the past eighteen months the Company has initiated sales, marketing, and regulatory activities in multiple countries in the region, including the initiation of product registrations in Japan and China, as well as increased sales activities in Hong Kong and countries of the ASEAN (Association of South-East Asian Nations) region.

The SUPERA stent was designed and engineered to mimic the structure and function of vascular anatomy.  Clinical evidence demonstrates that SUPERA is the most fracture resistant stent available, with excellent outcomes even in challenging anatomical areas.

About IDEV Technologies, Incorporated

IDEV Technologies, Inc. (IDEV) is a developer of endovascular technologies designed to protect and restore anatomical function. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

For more information please visit www.idevmd.com or www.device.com.au.

About Private Healthcare Australia Limited

Private Healthcare Australia Limited, formerly known as the Australian Health Insurance Association is the Australian private health industry's peak representative body that represents 23 health funds throughout Australia and collectively covers over 95% of the private health insurance industry.

Private Healthcare Australia member funds today provide healthcare benefits for approximately 12 million Australians.

For more information please visit http://www.privatehealthcareaustralia.org.au.